Objective: This study reports the technical success and follow-up results of transcatheter embolization of type I endoleak (ELI) in 25 patients after endovascular aortic repair (EVAR).
Type I endoleaks (ELI) are one of the leading factors necessitating intervention after endovascular aortic repair (EVAR) and are reported in up to 10% of EVAR cases. 1 ELI results from an inadequate seal at the proximal (type Ia [ELIa]) or distal (type Ib [ELIb] ) attachment sites of the aortic endograft. The resultant communication between the high pressure aortic lumen and the perigraft space can result in increased sac pressurization (endotension) and sac expansion. Treatment of ELI is advocated because of the risk of rupture and lack of spontaneous resolution. 2 Standard treatment options for an ELIa include proximal balloon dilation, proximal aortic cuffs, large-caliber balloonexpandable stents in the aneurysm neck, fenestrated aortic cuffs, and chimney grafts. The standard method for the treatment of ELIb is distal endograft extension. [3] [4] [5] [6] A small minority of patients are not suitable for these procedures because of adverse anatomy, such as a short or highly angulated proximal neck, or severe comorbidities that prohibit general anesthesia or open surgical repair. Some patients may have persistent ELIa or ELIb despite treatment with the standard methods. Transcatheter embolization offers an alternative percutaneous approach for ELI management in patients who are unsuitable for or refractory to conventional treatments. There is limited literature on the feasibility and effectiveness of embolization for ELI. We have previously reported our initial experience in six ELI cases after conventional EVAR 5 and five cases after aortic repair with Nellix endovascular aneurysm sealing (EVAS; Endologix, Santa Rosa, Calif). 7 In this article we present our results in a larger cohort with longer follow-up data.
METHODS
Patients. This is a retrospective observational study of all ELI cases treated by embolization at a tertiary referral center between October 2010 and August 2015. Local Ethics Committee approval was not required. Twentyfive patients (20 men, 5 women; mean age 80 years; range, 64-96 years) underwent 27 ELI embolization procedures.
Transcatheter embolization was selected for treatment in each patient after review and discussion in a multidisciplinary meeting. Informed written consent was obtained in all patients before treatment. Embolization of the endoleaks was selected as the treatment option for patients deemed unsuitable or refractory to conventional treatments. For patients, who had undergone EVAS with Nellix endografts, embolization was the primary treatment in view of the very limited alternative methods for ELI treatment after EVAS.
Of the 25 patients included in the study, 23 had undergone aortic repair for abdominal aortic aneurysm, one for a thoracic aortic aneurysm, and one for a thoracoabdominal aneurysmal dissection of the aorta. Twenty-three patients presented with an ELIa and two with an ELIb. Of the latter two, one endoleak was related to the distal end of a thoracic endograft and another to the distal end of an aortouniiliac endograft. The endograft type in each patient who underwent embolization is presented in Table I .
Embolization technique. The embolization technique has been previously fully described. 5 The standard technique is described briefly below. Retrograde common femoral artery (CFA) access is obtained. For ELIa embolization, a 45-cm 6F sheath (eg, Destination, Terumo Corp, Tokyo, Japan) is advanced into the aorta with the sheath tip a few centimeters below the top of the endograft. An aortogram is performed to assess the size, geometry, and neck of the endoleak. In most procedures, a reverse curved-shaped catheter (eg, 5F Simmons; Cook Inc, Bloomington, Ind) is used to selectively catheterize the endoleak cavity. A microcatheter (eg, 2.7F Progreat [Terumo Corp], Marathon or Echelon [Medtronic, Santa Rosa, Calif], or 2.95F PX SLIM [Penumbra, Alameda, Calif]) is advanced coaxially into the endoleak cavity. An endoleakogram is performed to better define the size of the endoleak and evaluate for the occasional presence of any exit vessels. The endoleakogram can also be used as a road map for the embolization.
Embolization is performed with Onyx (ev3 Endovascular, Inc, Plymouth, Minn) only or with coils and Onyx. If coils are combined with Onyx, we favor the use of detachable coils, such as Ruby (Penumbra) or Concerto (Medtronic), because of the potential for coil misplacement and migration out of the endoleak cavity. Coils are deployed to form a scaffold in the endoleak cavity. Onyx is injected into the interstices between the coils to achieve complete occlusion of the endoleak cavity. Before Onyx injection, the dead space of the catheter is replaced with a set volume of dimethyl sulfoxide depending on the type of microcather used. We routinely use Onyx-34 for ELI embolization, given its higher viscosity compared with Onyx 18, which may produce a better seal of the endoleak cavity with a reduced risk of reflux. Close intermittent fluoroscopic surveillance is used while Onyx is injected, given the risk of Onyx reflux, particularly in wide-necked endoleaks. Injection of Onyx is stopped upon complete filling of the endoleak cavity. A completion aortography is performed to assess for residual endoleak filling (Fig 1) .
For ELIb embolization, the procedure and steps are similar, apart from the use of a short regular sheath at the access site, angiography being performed at the distal end of the graft and with the use of an angledtip catheter (eg, cobra-shaped) to engage the endoleak cavity (Fig 2) .
With ELIa embolization after Nellix EVAS, it is important to consider the location of the endoleak in relation to the endograft limbs and the site of access most favorable for accessing the endoleak. For example, an endoleak on the left of the endoleak sac is usually easier to access from a right CFA approach, given the endografts cross over at the aortic bifurcation, and therefore, the right iliac limb graft is located on the left in the upper abdominal aorta. 7 Finally, an upper extremity brachial artery access may be used when endoleak access is difficult from a CFA approach.
Definition of success and follow-up. Technical success was defined as the elimination of the endoleak on completion angiography. Freedom from endoleak recurrence was defined as no visible residual endoleak on follow-up imaging. Freedom from sac growth was defined as a stable or decrease in aneurysm sac diameter. All patients were monitored clinically and by interval imaging according to standard local protocols. Follow-up imaging was performed by duplex ultrasound (US) imaging, computed tomography angiography (CTA), or both.
Imaging. All CTA scans were reviewed by a senior vascular interventional radiologist with >20 years' experience who also performed all of the embolization procedures. The aneurysm sac diameter before and after EVAR and after embolization was measured at the largest short-axis axial dimension. A change of >5 mm was deemed significant. Duplex US scans were performed by specialized vascular sonographers. CTA scans are performed using the GE VCT 64 slice scanner (GE Healthcare, Waukesha, Wisc) after administration of 90 mL nonionic contrast medium (300 mg I/mL at 5 mls/s) by a power injector into an 18-gauge venous access catheter in the antecubital vein. Scans are obtained in the arterial phase and extended from the thoracic inlet to the CFA bifurcation, with scan delay determined by bolus tracking over a region of interest over the aorta. A combination of CT and duplex US imaging is used where possible for follow-up after embolization. Aortic sac size is most accurately assessed on CT; however, identification of endoleak recurrence is limited by streak artifact from the tamsulosin content of Onyx as well as coils, if used in large quantity. Therefore, although large endoleak recurrences are visible on CT, smaller ones may only be visible on duplex imaging, which is not limited by streak artifact.
RESULTS
The endoleak diagnosis in 27 embolizations was based on CTA in 23 and on duplex US imaging in four. The average aneurysm sac size before embolization was 8.2 cm (range, 5.3-12.9 cm). The average time between EVAR and endoleak diagnosis was 685 days (range, 1-4220 days). The endoleak was diagnosed #10 days after EVAR in 7 patients, between 11 days and 7 months in 2, and >7 months in 16. The average time from endoleak diagnosis to embolization was 27 days (range, 2-94 days).
Access was through the CFA in 25 procedures and through the brachial artery in two. Detachable microcoils, between 2 and 11 of Ruby (Penumbra) or Concerto (ev3 Inc) coils, ranging between 4 and 12 mm, and Onyx (average, 9 mL; range, 2-83 mL), depending on the size of the endoleak, were used for embolization. Onyx alone was used in 16 procedures, and Onyx and coils were used in 11 procedures.
Procedural outcome. Immediate technical success with complete occlusion of the endoleak on postembolization completion angiography was achieved in all cases (100%).
There were six procedural complications, none of which had long-term sequelae. Three patients developed puncture site hematomas, two of which required surgical revision. Onyx reflux occurred at the end of the embolization procedure in three cases. Two of these happened within one of two Nellix endograft limbs and were both treated successfully by placement of an additional stent to affix the Onyx between the outside wall of the newly placed stent and the inside wall of the Nellix endograft. In another patient with a conventional aortouniiliac endograft, a small amount of Onyx reflux into the right iliac endograft was observed. However, this was not thought to be significant at the time and was not treated. This reflux did not cause symptoms and was not apparent on follow-up CT imaging.
Follow-up. The mean imaging follow-up available after embolization is 311 days (range, 1-1357 days). Of the 25 patients, 10 had both CTA and US follow-up, 12 had US only, and 2 had CTA only. One patient had no follow-up imaging and was excluded from the follow-up analysis.
Seven patients developed recurrent ELI (Table II) during the follow-up period. Two patients underwent a second embolization procedure. Both embolization procedures were performed on the basis that they would likely be palliative rather than curative measures. One of these two patients has had no further endoleak recurrence. The other patient (patient 2) had initially presented with CT evidence of impending sac rupture and a significantly enlarged aneurysm sac size (from 5 to 9.9 cm) owing to distal migration of the endograft causing a large ELIa. He survived 5 months after the second embolization procedure before dying of sac rupture. Two of the other five cases of endoleak recurrence were successfully managed by aortic cuff placement and Nellix endograft placement, and one had a persistent endoleak despite subsequent aortic cuff placement and died of sac rupture nearly 2.5 years after the embolization. These three patients were initially treated by embolization due to multiple comorbidities; however, after endoleak recurrence, the other options were revisited, and after discussion with the patient, including operative risk, the option of aortic cuff or Nellix revision was felt to be appropriate. The other two were deemed unsuitable for further intervention because of multiple comorbidities and endoleak morphology. One of the latter two patients also died of sac rupture, and one patient died of nonvascular causes. The freedom from endoleak recurrence at a mean follow-up of 311 days was 80% (Fig 3) .
Of 26 cases of ELI embolization with follow-up imaging, sac size decreased in 10 (38.5%), was stable in 10 (38.5%), and increased in 6 (23%). The freedom from sac growth after embolization was 85% at a mean follow-up of 311 days.
Eight endoleak recurrences (two in the same patient) were observed. There were 5 cases with an increase in sac size, 2 with a stable sac size, and 1 with reduced sac size (Table III) . There was a trend for higher rates of endoleak recurrence and increasing sac size after embolization in cases with a large aortic sac size at embolization (Tables IV and V) .
Seven of the eight endoleak recurrences had been embolized with Onyx only, and in only one patient had a combination of Onyx and coils been used (Table VI) .
DISCUSSION
There is general consensus on the need for early treatment of ELI. 8 Where conventional techniques have failed or are unsuitable and there is prohibitive surgical risk, transcatheter embolization offers an alternative management option. 9 The procedure is not generally long, does not require general anesthesia, and can be performed as a day case. Transcatheter ELI embolization was first described in 1997 by Golzarian et al, 10 who reported embolization of eight perigraft endoleaks, including five ELI cases (3 with ELIa and 2 ELIb) using coils only or coils and gelatin sponge, with technical success in all cases at 4 to 9 months' follow-up, and one patient requiring a repeat procedure. The same authors later briefly described their updated results as part of a review article on endoleak management, with reported technical success in 29 of 32 cases and two cases of endoleak recurrence. 11 There have since been several published case series using a variety of agents, including coils, Gelfoam (Pfizer, New York, NY), thrombin, and N-butyl cyanoacrylate (NBCA), or a combination of these. Several case reports on ELI embolization have also been published. [12] [13] [14] [15] [16] [17] The available published evidence of ELI embolization is summarized in with ELIa and two with ELIb, with one ELIa recurrence. We previously reported our early experience of ELI embolization with Onyx in six patients after conventional EVAR 5 and in seven after Nellix EVAS. 7 Here we report the early and midterm outcomes in 25 patients who underwent 27 embolization procedures. Although technical success based on elimination of endoleak on completion angiography after embolization was achieved in all 27 procedures, there were eight endoleak recurrences, including two in one patient who had two embolization procedures. This is the largest reported series of patients with ELI who have undergone embolization using Onyx (or Onyx and coils) to date.
ELIa embolization is usually a procedure of last resort when other bailout techniques have failed or are not possible. The one exception is when Nellix endografts are used for EVAR. These consist of two balloonexpandable stents that extend from the iliac arteries to the nonaneurysmal upper abdominal aorta and provide sealing of the aneurysm through polymer-filled endobags that surround the stent. Patients with Nellix endografts are not suitable for conventional ELIa treatments, and at our center, transcatheter embolization is the primary way of managing proximal endoleaks with these endografts. Moreover, our results show a more favourable embolization outcome with Nellix endografts than with conventional endografts (Fig 4) , with only one endoleak recurrence in 11 patients in this series, and this was subsequently successfully managed with a second embolization procedure. The other notable trend in our cohort is that of better outcomes when coils and Onyx are used together than when Onyx is solely used. When the former technique is used, we initially deploy detachable coils in the endoleak cavity to form a "scaffold" for subsequent complete Kaplan-Meier curves demonstrate freedom from (left) endoleak recurrence and (right) sac size increase after embolization, subdivided into cases with the Nellix (Endologix, Santa Rosa, Calif) endograft compared with conventional endovascular aortic repair (EVAR). There was one endoleak recurrence within the Nellix cohort at 395 days after embolization but no sac size increase.
Fig 5.
Large endoleak with unfavorable morphology for embolization. a and b, A computed tomography angiogram (CTA) 3 years after endovascular aortic repair (EVAR) shows distal migration of the endograft, a contained endoleak rupture, and a large type Ia endoleak (ELIa; arrow), w80 mL, with a wide neck measuring 4.1 cm. c, Embolization procedure: single exposure shows microcatheter tip (arrowhead) advanced into the base of the endoleak after catheterization with a reverse-shaped catheter. d, Endoleak cavity progressively filled with Onyx (ev3 Endovascular, Inc, Plymouth, Minn) under close monitoring. CTA images obtained 3 days after embolization in (e) axial and (f) sagittal views show filling of the endoleak cavity with Onyx and no endoleak visible; however, (g) axial and (h) sagittal CTA images at 101 days after embolization clearly show recurrent endoleak at the proximal end of the graft. h, Note the Onyx material appears to have migrated inferiorly within the aneurysm sac (arrow) on the sagittal image, and there is consequent patency of the endoleak neck on the axial image. Patient had multiple comorbidities, and a further embolization procedure was deemed not appropriate. occlusion of the endoleak by Onyx embolization. In our experience this approach has also minimized the risk of nontarget embolization: two of the three cases of Onyx reflux in our cohort were embolized without the use of coils.
Regarding whether there are any specific morphologic characteristics of ELI that are favorable predictors for a successful and durable embolization outcome, we have noticed that large endoleak cavities and endoleaks with a wide-necked communication (endoleak entrance) with the native artery lumen are more difficult to embolize and seem to have a less durable outcome. Large endoleak cavities require a large volume of embolic agent, and occluding the cavity completely in these cases is difficult. Successful endoleak occlusion in a large endoleak cavity may be achieved by occluding the entrance into the endoleak.
Wide-necked endoleaks pose a particular challenge because these exhibit an inherent high risk of Onyx reflux, which is further elevated by the need to achieve a complete seal of the endoleak cavity and requires the embolic agent to be placed at the endoleak neck. If we have to embolize an endoleak with a wide neck, a combination of detachable coils and Onyx seems to be optimal. We have not analyzed morphologic endoleak characteristics to determine an unfavorable threshold value for endoleak cavity size or endoleak entrance diameter for embolization. However, we believe that an endoleak cavity volume of >30 mL and an endoleak entrance of >15 mm are unfavorable predictors of early or late success.
As a result of our experience, we do not advocate embolization for all patients with ELI that are unsuitable for standard therapies; however, there are few situations where embolization cannot be attempted. In cases, such as those with large endoleak cavities or wide endoleak entrances, where embolization is unlikely to provide a long-term sustained endoleak occlusion, these patients may benefit from ELI embolization as a palliative measure to prevent sac growth and rupture for as long as possible (Fig 5) . In this series, palliative endoleak embolization prolonged the lives of the two patients, who presented with an impending abdominal aortic aneurysm rupture, for 5 and 4 months, proving that palliative embolization should be considered in patients without any other alternative.
CONCLUSIONS
This series is the largest cohort of patients with ELI who have undergone embolization with Onyx or Onyx and coils. Transcatheter embolization of ELI provides a safe and sustainable treatment option for patients refractory or unsuitable for conventional ELI therapeutic options. Embolization has a high technical success rate, a low endoleak recurrence rate, and most patients are free from aneurysm sac growth. Patients with large endoleak cavities and wide endoleak entrances may have less predictable outcomes after embolization, although freedom from aortic rupture and freedom from sac growth may be a desirable therapeutic goal of embolization in these patients. 
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